136 related articles for article (PubMed ID: 30848190)
21. Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.
Ortholan C; Durivault J; Hannoun-Levi JM; Guyot M; Bourcier C; Ambrosetti D; Safe S; Pagès G
Eur J Cancer; 2010 Nov; 46(16):3022-36. PubMed ID: 20729074
[TBL] [Abstract][Full Text] [Related]
22. Serum vascular endothelial growth factor A (VEGF) is elevated in patients with ovarian granulosa cell tumor (GCT), and VEGF inhibition by bevacizumab induces apoptosis in GCT in vitro.
Färkkilä A; Pihlajoki M; Tauriala H; Bützow R; Leminen A; Unkila-Kallio L; Heikinheimo M; Anttonen M
J Clin Endocrinol Metab; 2011 Dec; 96(12):E1973-81. PubMed ID: 21994955
[TBL] [Abstract][Full Text] [Related]
23. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant nivolumab plus bevacizumab therapy improves the prognosis of triple-negative breast cancer in humanized mouse models.
Zheng H; Wu L; Chen J; Na N; Lou G
Breast Cancer; 2024 May; 31(3):371-381. PubMed ID: 38289410
[TBL] [Abstract][Full Text] [Related]
25. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
26. Berberine Suppresses Cell Motility Through Downregulation of TGF-β1 in Triple Negative Breast Cancer Cells.
Kim S; Lee J; You D; Jeong Y; Jeon M; Yu J; Kim SW; Nam SJ; Lee JE
Cell Physiol Biochem; 2018; 45(2):795-807. PubMed ID: 29414799
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.
Gyanchandani R; Sano D; Ortega Alves MV; Klein JD; Knapick BA; Oh S; Myers JN; Kim S
Oral Oncol; 2013 Aug; 49(8):761-70. PubMed ID: 23623402
[TBL] [Abstract][Full Text] [Related]
28. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.
Di Mauro C; Rosa R; D'Amato V; Ciciola P; Servetto A; Marciano R; Orsini RC; Formisano L; De Falco S; Cicatiello V; Di Bonito M; Cantile M; Collina F; Chambery A; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2017 May; 116(11):1425-1435. PubMed ID: 28441382
[TBL] [Abstract][Full Text] [Related]
29. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.
Inoue S; Hartman A; Branch CD; Bucana CD; Bekele BN; Stephens LC; Chada S; Ramesh R
Mol Ther; 2007 Feb; 15(2):287-94. PubMed ID: 17235306
[TBL] [Abstract][Full Text] [Related]
30. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45.
Li H; Adachi Y; Yamamoto H; Min Y; Ohashi H; Ii M; Arimura Y; Endo T; Lee CT; Carbone DP; Imai K; Shinomura Y
Cancer; 2011 Jul; 117(14):3135-47. PubMed ID: 21264842
[TBL] [Abstract][Full Text] [Related]
31. Effects of aflibercept and bevacizumab on cell viability, cell metabolism and inflammation in hypoxic human Müller cells.
Matsuda M; da Silva RA; Roda VMP; Marquezini MV; Monteiro MLR; Hamassaki DE
PLoS One; 2024; 19(3):e0300370. PubMed ID: 38536827
[TBL] [Abstract][Full Text] [Related]
32. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
33. Molecular hierarchy of heparin-binding EGF-like growth factor-regulated angiogenesis in triple-negative breast cancer.
Yotsumoto F; Tokunaga E; Oki E; Maehara Y; Yamada H; Nakajima K; Nam SO; Miyata K; Koyanagi M; Doi K; Shirasawa S; Kuroki M; Miyamoto S
Mol Cancer Res; 2013 May; 11(5):506-17. PubMed ID: 23443317
[TBL] [Abstract][Full Text] [Related]
34. Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO
Zhu R; Wang Z; Liang P; He X; Zhuang X; Huang R; Wang M; Wang Q; Qian Y; Wang S
Acta Biomater; 2017 Nov; 63():163-180. PubMed ID: 28923539
[TBL] [Abstract][Full Text] [Related]
35. Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts.
Kristian A; Revheim ME; Qu H; Mælandsmo GM; Engebråten O; Seierstad T; Malinen E
Acta Oncol; 2013 Oct; 52(7):1566-72. PubMed ID: 23984812
[TBL] [Abstract][Full Text] [Related]
36. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
37. Silibinin inhibits triple negative breast cancer cell motility by suppressing TGF-β2 expression.
Kim S; Han J; Jeon M; You D; Lee J; Kim HJ; Bae S; Nam SJ; Lee JE
Tumour Biol; 2016 Aug; 37(8):11397-407. PubMed ID: 26984157
[TBL] [Abstract][Full Text] [Related]
38. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous application of bevacizumab and anti-CTGF antibody effectively suppresses proangiogenic and profibrotic factors in human RPE cells.
Bagheri A; Soheili ZS; Ahmadieh H; Samiei S; Sheibani N; Astaneh SD; Kanavi MR; Mohammadian A
Mol Vis; 2015; 21():378-90. PubMed ID: 25883524
[TBL] [Abstract][Full Text] [Related]
40. Combination of Fish Oil and Selenium Enhances Anticancer Efficacy and Targets Multiple Signaling Pathways in Anti-VEGF Agent Treated-TNBC Tumor-Bearing Mice.
Guo CH; Hsia S; Chung CH; Lin YC; Shih MY; Chen PC; Hsu GW; Fan CT; Peng CL
Mar Drugs; 2021 Mar; 19(4):. PubMed ID: 33805447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
